CASE OF SHORT DURATION OF SYNCOPE AFTER 8 MONTHS OF ANGIOPLASTY, TICAGRELOR WAS CULPRIT
Dr. Naresh Sen*
ABSTRACT
Dual antiplatelet therapy with aspirin and P2Y12 platelet receptor inhibitor is a cornerstone of treatment in acute coronary syndrome (ACS). Ticagrelor is a novel, potent, direct P2Y12 antagonist with rapid onset of action and intense, consistent platelet reactivity inhibition. In patients with ACS ticagrelor was superior to clopidogrel in decreasing major adverse cardiac events. Ticagrelor is an antiplatelet agent prescribed to prevent the development of adverse cardiac events after acute coronary syndrome (ACS). According to the PLATO trial, ticagrelor is associated with ventricular pauses in the first week of treatment; however, these episodes were felt to be asymptomatic and nonfatal to the patient. We present a case of ticagrelor related second-degree type II heart block causing severe dizziness and diaphoresis that resolved after discontinuation of the medication. our aim is to increase awareness of ticagrelor related bradycardia or syncope and focus on its prevention.
[Full Text Article] [Download Certificate]